The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- PMID: 25214542
- PMCID: PMC6267863
- DOI: 10.1093/annonc/mdu450
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Abstract
Background: The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC.
Design: A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches.
Conclusions: The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
Keywords: breast cancer (BC); clinical validity; prediction; prognosis; tumor-infiltrating lymphocytes (TILs).
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6267863/bin/mdu45001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6267863/bin/mdu45002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6267863/bin/mdu45003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6267863/bin/mdu45004.gif)
Comment in
-
Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method.Ann Oncol. 2015 Nov;26(11):2351. doi: 10.1093/annonc/mdv363. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347098 No abstract available.
Similar articles
-
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.Int J Mol Sci. 2017 Sep 8;18(9):1936. doi: 10.3390/ijms18091936. Int J Mol Sci. 2017. PMID: 28885584 Free PMC article.
-
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Semin Cancer Biol. 2018. PMID: 29024776 Review.
-
Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.Acta Oncol. 2018 Jan;57(1):90-94. doi: 10.1080/0284186X.2017.1403040. Epub 2017 Nov 23. Acta Oncol. 2018. PMID: 29168428
-
Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014.Ann Diagn Pathol. 2018 Aug;35:77-79. doi: 10.1016/j.anndiagpath.2018.05.007. Epub 2018 May 31. Ann Diagn Pathol. 2018. PMID: 29886396
-
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.Breast Cancer Res Treat. 2014 Dec;148(3):467-76. doi: 10.1007/s10549-014-3185-2. Epub 2014 Nov 1. Breast Cancer Res Treat. 2014. PMID: 25361613 Review.
Cited by
-
The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy.J Natl Cancer Cent. 2024 Jan 26;4(1):14-24. doi: 10.1016/j.jncc.2024.01.004. eCollection 2024 Mar. J Natl Cancer Cent. 2024. PMID: 39036381 Free PMC article. Review.
-
Causal effects and metabolites mediators between immune cell and risk of breast cancer: a Mendelian randomization study.Front Genet. 2024 May 17;15:1380249. doi: 10.3389/fgene.2024.1380249. eCollection 2024. Front Genet. 2024. PMID: 38826800 Free PMC article.
-
PIK3CA mutations in endocrine-resistant breast cancer.Sci Rep. 2024 May 31;14(1):12542. doi: 10.1038/s41598-024-62664-1. Sci Rep. 2024. PMID: 38822093 Free PMC article.
-
Predictive Factors of Neoadjuvant Chemotherapy Response in Breast Cancer Validated by Three Anatomopathological Scores: Residual Cancer Burden, Chevallier System, and Tumor-Infiltrating Lymphocytes.Cureus. 2024 Apr 30;16(4):e59391. doi: 10.7759/cureus.59391. eCollection 2024 Apr. Cureus. 2024. PMID: 38817506 Free PMC article.
-
Assessment of novel prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design.Ther Adv Med Oncol. 2024 May 24;16:17588359241248329. doi: 10.1177/17588359241248329. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38800567 Free PMC article.
References
-
- Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials